Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NW-101C in advanced solid tumors
NCT07266298Phase 1Recruiting
- Sponsor
- Neowise Biotechnology
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NW-101C in Non-hematologic malignancy, sponsored by Neowise Biotechnology. Primary endpoints: Dose-limiting toxicities at 28 days and Maximum Tolerated Dose at 2 years. Started Dec 2025; status: recruiting.
02
Drugs
NW-101C
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on NCT07266298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266298.